Participated · Equity · Oct 2025

iOrganBio is a 2024-founded biotech company leveraging its proprietary CellForge™ platform to industrialize the production of human cells and organoids for drug discovery, regenerative medicine, and cell therapies. CellForge integrates AI-based predictive modeling with high-throughput, closed-loop control of 3D culture environments to optimize human pluripotent stem cell differentiation in real time. Central to the system is the Functional Human CellAtlas™, a growing single-cell multi-omics database that serves as a digital blueprint for engineering targeted cell states. Early applications include generating pancreas models with tailored vasculature and immune competency by selectively producing beta islet cells. The company addresses key industry bottlenecks—definability, generalizability, adaptability, reproducibility, and scalability—to deliver reproducible and cost-effective cell manufacturing. iOrganBio is headquartered at BioLabs in Chapel Hill, NC and currently operates with $2 million in initial capital; no revenue or user metrics were disclosed.